Study guide

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations

Key Takeaways Explain This Topic AI

Total Body Water (TBW) constitutes 60% of adult body weight (70% in infants, 50% in elderly/females), divided into Intracellular Fluid (ICF, 40% of body weight / 2/3 of TBW) and Extracellular Fluid (ECF, 20% of body weight / 1/3 of TBW; partitioned into Interstitial Fluid [ISF, 15%] and Intravascular Fluid [IVF, 5%]).

0.9% Normal Saline has an osmolarity of 308 mOsm/L with supraphysiological sodium (154 mEq/L) and chloride (154 mEq/L), which causes normal anion gap hyperchloremic metabolic acidosis and renal vasoconstriction leading to reduced renal cortical perfusion and GFR.

Balanced crystalloids (Lactated Ringer's [273 mOsm/L, 130 Na+, 109 Cl-, 4 K+, 3 Ca2+, 28 lactate] and Plasma-Lyte [294 mOsm/L, 140 Na+, 98 Cl-, 5 K+, 3 Mg2+, acetate/gluconate]) maintain physiological pH; LR is slightly hypotonic and contraindicated in traumatic brain injury (TBI) and should not be co-administered with PRBCs due to calcium chelating with citrate.

Colloids provide oncotic expansion: 5% Albumin (COP ~20 mmHg) expands intravascular volume 1:1, while 25% Albumin (hyper-oncotic, COP ~70–100 mmHg) draws ~4–5 mL of fluid from the interstitium for every 1 mL infused; Hydroxyethyl starches (HES) carry FDA black-box warnings for nephrotoxicity (AKI/RRT) and cause acquired coagulopathy by reducing Factor VIII/vWF activity.

Goal-Directed Fluid Therapy (GDFT) utilizes dynamic cardiopulmonary interactions (Stroke Volume Variation [SVV] >12–13%, Pulse Pressure Variation [PPV] >12–13%, and Stroke Volume rise >10% after a fluid challenge) in mechanically ventilated sinus-rhythm patients to guide volume responsiveness, outperforming static metrics like CVP and blood pressure.

Last updated: August 2026

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations

Intraoperative fluid management is a fundamental competency in nurse anesthesia practice. The primary goals of intravenous fluid therapy are to maintain effective circulating intravascular volume, preserve cardiac preload and tissue perfusion, maintain normal electrolyte balance and acid-base homeostasis, and replace ongoing surgical losses without inducing tissue edema or hypervolemic glycocalyx shedding.

1. Body Fluid Compartments & The Endothelial Glycocalyx

Total body water (TBW) and its distribution across internal fluid compartments vary predictably based on age, gender, and adipose composition. +-------------------------------------------------------------------------+

  • | TOTAL BODY WATER (TBW) COMPARTMENTS |
  • | (60% of Body Weight in 70-kg Adult) |
  • +------------------------------------+------------------------------------+
  • | INTRACELLULAR FLUID (ICF) | EXTRACELLULAR FLUID (ECF) |
  • | 40% Body Weight | 20% Body Weight |
  • | (2/3 of TBW = ~28 Liters) | (1/3 of TBW = ~14 Liters) |
  • | - Major Cation: K+, Mg2+ +-----------------+------------------+
  • | - Major Anions: Phosphates, | Interstitial | Intravascular |
  • | Proteins, Sulfates | Fluid (ISF) | Fluid (IVF) |
  • | | 15% Body Weight | 5% Body Weight |
  • | | (~10.5 Liters) | (~3.5 Liters) |
  • +------------------------------------+-----------------+------------------+
  • Compartment Fractions & Physiological Benchmarks

Total Body Water (TBW):

Adult male: 60 % 60\% 60% of total body weight ( 0.60 × kg 0.60 \times \text{kg} 0.60 × kg ).

Adult female: 50 % 50\% 50% of total body weight (lower due to higher body fat percentage).

Full-term infant: 70 − 75 % 70 - 75\% 70 − 75% of total body weight.

Premature neonate: 80 % 80\% 80% of total body weight.

Elderly adult: 50 − 55 % 50 - 55\% 50 − 55% of total body weight (loss of lean muscle mass).

Intracellular Fluid (ICF): 40 % 40\% 40% of body weight ( 2 / 3 2/3 2/3 of TBW, ≈ 28 L \approx 28\text{ L} ≈ 28 L in a 70-kg adult). Primary intracellular cation is Potassium ( K + K^+ K + ); primary intracellular anions are organic phosphates and proteins.

Extracellular Fluid (ECF): 20 % 20\% 20% of body weight ( 1 / 3 1/3 1/3 of TBW, ≈ 14 L \approx 14\text{ L} ≈ 14 L in a 70-kg adult). Primary extracellular cation is Sodium ( N a + Na^+ N a + ); primary extracellular anion is Chloride ( C l − Cl^- C l − ).

Interstitial Fluid (ISF): 15 % 15\% 15% of body weight ( 3 / 4 3/4 3/4 of ECF, ≈ 10.5 L \approx 10.5\text{ L} ≈ 10.5 L in a 70-kg adult). Extravascular fluid bathing parenchymal cells.

Intravascular Fluid (IVF / Plasma Volume): 5 % 5\% 5% of body weight ( 1 / 4 1/4 1/4 of ECF, ≈ 3.5 L \approx 3.5\text{ L} ≈ 3.5 L in a 70-kg adult).

Total Blood Volume (TBV): Plasma volume plus Red Blood Cell (RBC) volume ( ≈ 2.1 L \approx 2.1\text{ L} ≈ 2.1 L ). Average adult TBV is approximately 70 mL/kg 70\text{ mL/kg} 70 mL/kg in males and 65 mL/kg 65\text{ mL/kg} 65 mL/kg in females (total ≈ 5 L \approx 5\text{ L} ≈ 5 L in a 70-kg individual).

The Endothelial Glycocalyx Layer & Revised Starling Model

The vascular endothelial luminal surface is coated with the endothelial glycocalyx , a 0.5–1.0 µm thick, negatively charged mesh of membrane-bound proteoglycans (syndecans, glypicans), glycosaminoglycans (heparan sulfate, chondroitin sulfate, hyaluronic acid), and adsorbed plasma proteins (principally albumin).

Revised Starling Principle: Fluid filtration across intact capillaries is determined by the trans-endothelial oncotic pressure difference between the intravascular space and the subglycocalyx space (not the broad interstitial space). Because the subglycocalyx space is essentially protein-free, no physiological reabsorption of fluid occurs at the venous end of the capillary bed; filtered fluid returns to the circulation almost exclusively via lymphatic drainage.

Glycocalyx Degradation: Hypervolemia, rapid crystalloid boluses (triggering Atrial Natriuretic Peptide [ANP] release), ischemia-reperfusion, sepsis, and surgical trauma strip the glycocalyx. Shedding increases capillary permeability, accelerates transvascular fluid extravasation, and produces diffuse tissue edema.

2. Crystalloid Solutions: Composition & Clinical Distinctions

Crystalloids are aqueous solutions of mineral salts and water-soluble molecules that freely cross capillary semipermeable membranes and distribute across the entire extracellular fluid (ECF) volume. Because the intravascular volume comprises only 20–25% of the ECF space, only 200–250 mL of every 1,000 mL of isotonic crystalloid remains intravascularly 30–60 minutes after rapid infusion, with 750–800 mL equilibrating into the interstitial space.

Electrolyte Profiles of Common Intravenous Crystalloids

Solution N a + Na^+ N a + (mEq/L) C l − Cl^- C l − (mEq/L) K + K^+ K + (mEq/L) C a 2 + Ca^{2+} C a 2 + (mEq/L) M g 2 + Mg^{2+} M g 2 + (mEq/L) Buffer / Anion (mEq/L) Osmolarity (mOsm/L) pH

Plasma (Serum Reference) 135–145 96–106 3.5–5.0 4.5–5.5 1.5–2.5 H C O 3 − HCO_3^- H C O 3 − ​ (24–28) 285–295 7.35–7.45

  • 0.9% Normal Saline (NS) 154 154 0 0 0 None 308 ~5.5 (4.5–7.0)
  • Lactated Ringer's (LR) 130 109 4 3 0 Lactate (28) 273 ~6.5
  • Plasma-Lyte 148 / Normosol-R 140 98 5 0 3 Acetate (27), Gluconate (23) 294 7.4
  • 5% Dextrose in Water ( D 5 W D_5W D 5 ​ W ) 0 0 0 0 0 Dextrose ( 50 g/L 50\text{ g/L} 50 g/L ) 252 ~4.5
  • 0.45% Saline ( 1 / 2 1/2 1/2 NS) 77 77 0 0 0 None 154 ~5.0
  • High-Yield Clinical Properties of Crystalloids
  • 1. 0.9% Normal Saline (NS)

Strong Ion Difference (SID) & Acid-Base Impact: Normal Saline has a Strong Ion Difference ( [ N a + ] − [ C l − ] [Na^+] - [Cl^-] [ N a + ] − [ C l − ] ) of 0 mEq/L 0\text{ mEq/L} 0 mEq/L (compared to normal plasma SID of 38 − 42 mEq/L 38-42\text{ mEq/L} 38 − 42 mEq/L ). Infusing large volumes of 0.9% NS delivers an unphysiologic chloride load, reducing plasma SID and creating a hyperchloremic normal anion gap metabolic acidosis ( p H ↓ pH \downarrow p H ↓ , H C O 3 − ↓ HCO_3^- \downarrow H C O 3 − ​ ↓ , C l − ↑ Cl^- \uparrow C l − ↑ ).

Renal Hemodynamics: Hyperchloremia sensed by the macula densa triggers tubuloglomerular feedback, inducing renal afferent arteriolar vasoconstriction , decreasing renal cortical blood flow, lowering GFR, and increasing the risk of acute kidney injury (AKI).

Primary Indications: Hypochloremic hypokalemic metabolic alkalosis (e.g., severe vomiting, nasogastric suction, pyloric stenosis), hypercalcemia (promotes calciuresis), traumatic brain injury (TBI / elevated ICP), and dilution/co-administration with Packed Red Blood Cells (PRBCs).

2. Lactated Ringer's (LR)

Composition & Metabolism: Balanced crystalloid containing 28 mEq/L 28\text{ mEq/L} 28 mEq/L sodium lactate. In the liver, lactate is oxidized to pyruvate and metabolized via gluconeogenesis to bicarbonate ( 1 mmol lactate → 1 mmol H C O 3 − 1\text{ mmol lactate} \rightarrow 1\text{ mmol } HCO_3^- 1 mmol lactate → 1 mmol H C O 3 − ​ ), consuming hydrogen ions and preventing acidosis.

Slight Hypotonicity ( 273 mOsm/L 273\text{ mOsm/L} 273 mOsm/L ): LR is slightly hypotonic compared to plasma osmolarity ( 285 − 295 mOsm/L 285-295\text{ mOsm/L} 285 − 295 mOsm/L ). In patients with traumatic brain injury (TBI) , cerebral ischemia, or elevated intracranial pressure (ICP), infusing large volumes of hypotonic fluids decreases serum osmolarity, driving water along the osmotic gradient into brain tissue and exacerbating cerebral edema.

PRBC Incompatibility: LR contains 3 mEq/L 3\text{ mEq/L} 3 mEq/L ionized calcium ( C a 2 + Ca^{2+} C a 2 + ). Mixing LR directly with citrated blood products (PRBCs) overcomes the anticoagulant capacity of citrate, precipitating calcium-citrate chelation and microvascular clot formation within the IV infusion tubing.

3. Plasma-Lyte 148 & Normosol-R

Composition: True balanced isotonic crystalloid ( 294 mOsm/L 294\text{ mOsm/L} 294 mOsm/L ) matching plasma electrolyte composition with physiologic chloride ( 98 mEq/L 98\text{ mEq/L} 98 mEq/L ) and physiological pH (7.4).

Metabolism: Contains acetate ( 27 mEq/L 27\text{ mEq/L} 27 mEq/L ) and gluconate ( 23 mEq/L 23\text{ mEq/L} 23 mEq/L ) as bicarbonate precursors. Unlike lactate (which requires hepatic clearance), acetate is metabolized rapidly by peripheral skeletal muscle, making Plasma-Lyte the preferred balanced fluid in severe hepatic failure.

4. 5% Dextrose in Water ( D 5 W D_5W D 5 ​ W )

Free Water Distribution: D 5 W D_5W D 5 ​ W is isotonic in the bag ( 252 mOsm/L 252\text{ mOsm/L} 252 mOsm/L ). Once infused, dextrose ( 50 g/L = 5 g/100 mL 50\text{ g/L} = 5\text{ g/100 mL} 50 g/L = 5 g/100 mL ) is rapidly cleared and metabolized by endogenous insulin. What remains is hypotonic free water , which distributes uniformly across all total body water compartments in proportion to their baseline volumes ( 2 / 3 2/3 2/3 to ICF, 1 / 3 1/3 1/3 to ECF [only 1 / 12 1/12 1/12 or ≈ 8.3 % \approx 8.3\% ≈ 8.3% remains intravascularly]).

Intravascular Expansion: Infusing 1 , 000 mL 1,000\text{ mL} 1 , 000 mL of D 5 W D_5W D 5 ​ W expands plasma volume by only ≈ 83 mL \approx 83\text{ mL} ≈ 83 mL .

Neuroischemic Caution: Avoid in cerebral ischemia/stroke; hyperglycemia promotes anaerobic glycolysis in underperfused neurons, accumulating intracellular lactic acid and accelerating neuronal necrosis.

3. Colloid Solutions: Natural vs. Synthetic

Colloids are high-molecular-weight solutions that do not readily cross intact capillary membranes. They generate colloid oncotic pressure (COP) that retains fluid within the intravascular space. +-------------------------------------------------------------------------+

  • | COLLOID CHARACTERISTICS & ONCOTIC POWER |
  • +---------------------+-----------------------+---------------------------+
  • | Solution | Oncotic Pressure | Volume Expansion Profile |
  • +---------------------+-----------------------+---------------------------+
  • | 5% Human Albumin | COP ~20 mmHg | 1:1 Intravascular (100%) |
  • | 25% Human Albumin | COP ~70 - 100 mmHg | 4:1 to 5:1 (400 - 500%) |
  • | Hydroxyethyl Starch | High initial COP | 1:1 (Nephro/Coagulopathy) |
  • | Dextrans / Gelatins | High COP | Anaphylaxis / Crossmatch |
  • +---------------------+-----------------------+---------------------------+
  • Clinical Comparison of Colloid Formulations

5% Human Albumin (Iso-oncotic):

COP: ≈ 20 mmHg \approx 20\text{ mmHg} ≈ 20 mmHg (matches normal plasma COP).

Intravascular Yield: 1:1 volume expansion ( 500 mL 500\text{ mL} 500 mL infused produces ≈ 500 mL \approx 500\text{ mL} ≈ 500 mL intravascular volume expansion). Intravascular half-life is 16–24 hours when the glycocalyx is intact.

Preparation: Heat-treated ( 60 ∘ C 60^\circ\text{C} 6 0 ∘ C for 10 hours) during manufacturing, eliminating transmission risk of viral pathogens (HIV, Hepatitis B/C).

25% Human Albumin (Hyper-oncotic):

COP: ≈ 70 − 100 mmHg \approx 70 - 100\text{ mmHg} ≈ 70 − 100 mmHg (hyper-oncotic).

Interstitial Fluid Shift: Draws 4 − 5 mL 4 - 5\text{ mL} 4 − 5 mL of water from the interstitial space into the intravascular space for every 1 mL 1\text{ mL} 1 mL infused .

Intravascular Yield: Infusing a 100 mL 100\text{ mL} 100 mL bottle of 25% albumin expands intravascular plasma volume by 400 − 500 mL 400 - 500\text{ mL} 400 − 500 mL within 30–60 minutes.

Indications: Severe hypoalbuminemia in volume-overloaded states, post-large-volume paracentesis ( > 5 L >5\text{ L} > 5 L removed; administer 6–8 g albumin per liter of ascites removed), and hepatorenal syndrome.

Hydroxyethyl Starches (HES / Hetastarch / Hextend / Voluven):

Nephrotoxicity Black Box Warning: Synthetic polymer of modified amylopectin. Accumulates in renal reticuloendothelial cells, causing osmotic nephrosis, acute kidney injury (AKI), and increased requirement for renal replacement therapy (RRT) in critically ill and septic patients.

Acquired Coagulopathy: Coats circulating platelets (inhibiting GpIIb/IIIa activation), reduces plasma levels of Factor VIII and von Willebrand factor (vWF) , and impairs clot strength (lowers TEG Maximum Amplitude).

Dextrans & Gelatins:

Dextran-40 & Dextran-70: Synthetic glucose polymers. Associated with severe IgE-independent anaphylactoid reactions, erythrocyte coating (which interferes with blood type and crossmatch), and acute renal failure due to tubular obstruction.

Gelatins (Modified Bovine Collagen): High incidence of allergic/anaphylactic reactions due to histamine release.

4. Traditional Perioperative Fluid Calculations

Traditional fluid regimens rely on mathematical approximations to replace fasting maintenance, preoperative fluid deficits, and third-space tissue redistribution. +-------------------------------------------------------------------------+

  • | HOLLIDAY-SEGAR 4-2-1 MAINTENANCE RULE |
  • +--------------------+----------------------------------------------------+
  • | Weight Tier | Hourly Maintenance Rate |
  • +--------------------+----------------------------------------------------+
  • | First 10 kg | 4 mL/kg/hr (0 - 10 kg = up to 40 mL/hr) |
  • | Next 10 kg (11-20) | 2 mL/kg/hr (11 - 20 kg = up to 20 mL/hr) |
  • | Each kg above 20 kg| 1 mL/kg/hr for every kg > 20 kg |
  • +--------------------+----------------------------------------------------+
  • | SHORTCUT (wt >20kg)| Weight in kg + 40 = Hourly Maintenance Rate (mL/hr)|
  • +--------------------+----------------------------------------------------+
  • The 4-2-1 Rule & Shortcut Calculation

Formula Steps:

  • 0 − 10 kg 0 - 10\text{ kg} 0 − 10 kg : 4 mL/kg/hr 4\text{ mL/kg/hr} 4 mL/kg/hr
  • 11 − 20 kg 11 - 20\text{ kg} 11 − 20 kg : 2 mL/kg/hr 2\text{ mL/kg/hr} 2 mL/kg/hr
  • > 20 kg >20\text{ kg} > 20 kg : 1 mL/kg/hr 1\text{ mL/kg/hr} 1 mL/kg/hr

Quick Calculation Method (for patients > 20 kg >20\text{ kg} > 20 kg ): Maintenance Rate (mL/hr) = Patient Weight in kg + 40 \text{Maintenance Rate (mL/hr)} = \text{Patient Weight in kg} + 40 Maintenance Rate (mL/hr) = Patient Weight in kg + 40

  • Example (70-kg patient): 70 + 40 = 110 mL/hr 70 + 40 = 110\text{ mL/hr} 70 + 40 = 110 mL/hr
  • Example (85-kg patient): 85 + 40 = 125 mL/hr 85 + 40 = 125\text{ mL/hr} 85 + 40 = 125 mL/hr

Preoperative NPO Deficit & Replacement Schedule Total NPO Deficit (mL) = Hourly Maintenance Rate (mL/hr) × Hours NPO \text{Total NPO Deficit (mL)} = \text{Hourly Maintenance Rate (mL/hr)} \times \text{Hours NPO} Total NPO Deficit (mL) = Hourly Maintenance Rate (mL/hr) × Hours NPO

Replacement Fraction Schedule:

1st Hour of Anesthesia: 50 % 50\% 50% of total NPO deficit + + + hourly maintenance + + + surgical loss.

2nd Hour of Anesthesia: 25 % 25\% 25% of total NPO deficit + + + hourly maintenance + + + surgical loss.

3rd Hour of Anesthesia: 25 % 25\% 25% of total NPO deficit + + + hourly maintenance + + + surgical loss.

Third-Space & Surgical Tissue Trauma Losses

Third-space loss represents non-functional sequestration of fluid into traumatized interstitial tissue and evaporative loss from exposed peritoneal/pleural cavities:

Minimal Trauma (e.g., hernia repair, laparoscopic cholecystectomy, cataract, carpal tunnel): 0 − 2 mL/kg/hr 0 - 2\text{ mL/kg/hr} 0 − 2 mL/kg/hr

Moderate Trauma (e.g., open cholecystectomy, open hysterectomy, total knee arthroplasty): 2 − 4 mL/kg/hr 2 - 4\text{ mL/kg/hr} 2 − 4 mL/kg/hr

Severe Trauma (e.g., major open exploratory laparotomy, bowel resection, Whipple procedure, open AAA): 4 − 8 mL/kg/hr 4 - 8\text{ mL/kg/hr} 4 − 8 mL/kg/hr (up to 6 − 10 mL/kg/hr 6 - 10\text{ mL/kg/hr} 6 − 10 mL/kg/hr for massive resections)

Blood Loss Replacement Ratios

Crystalloid Replacement: 3 : 1 3:1 3 : 1 ratio ( 3 mL 3\text{ mL} 3 mL of balanced crystalloid for every 1 mL 1\text{ mL} 1 mL of estimated blood loss [EBL]) due to rapid redistribution into interstitial fluid.

Colloid or Blood Product Replacement: 1 : 1 1:1 1 : 1 ratio ( 1 mL 1\text{ mL} 1 mL of colloid, 5% albumin, or PRBCs for every 1 mL 1\text{ mL} 1 mL of EBL).

Comprehensive Traditional Calculation Case Example: A 70-kg male undergoing an open bowel resection (severe trauma, 6 mL/kg/hr 6\text{ mL/kg/hr} 6 mL/kg/hr ) has been NPO for 8 hours. Estimated blood loss during Hour 1 is 100 mL 100\text{ mL} 100 mL .

Hourly Maintenance: 70 + 40 = 110 mL/hr 70 + 40 = 110\text{ mL/hr} 70 + 40 = 110 mL/hr

NPO Deficit: 110 mL/hr × 8 hours = 880 mL 110\text{ mL/hr} \times 8\text{ hours} = 880\text{ mL} 110 mL/hr × 8 hours = 880 mL

Hour 1 Deficit Replacement (50%): 880 × 0.50 = 440 mL 880 \times 0.50 = 440\text{ mL} 880 × 0.50 = 440 mL

Third-Space Loss: 70 kg × 6 mL/kg/hr = 420 mL/hr 70\text{ kg} \times 6\text{ mL/kg/hr} = 420\text{ mL/hr} 70 kg × 6 mL/kg/hr = 420 mL/hr

EBL Replacement (3:1 crystalloid): 100 mL × 3 = 300 mL 100\text{ mL} \times 3 = 300\text{ mL} 100 mL × 3 = 300 mL Total Hour 1 Fluid Delivery: 110 (maint) + 440 (deficit) + 420 (3rd space) + 300 (EBL) = 1 , 270 mL 110\text{ (maint)} + 440\text{ (deficit)} + 420\text{ (3rd space)} + 300\text{ (EBL)} = \mathbf{1,270\text{ mL}} 110 (maint) + 440 (deficit) + 420 (3rd space) + 300 (EBL) = 1 , 270 mL .

5. Goal-Directed Fluid Therapy (GDFT) & Dynamic Hemodynamic Parameters

Modern anesthetic practice recognizes that aggressive, unguided crystalloid administration leads to tissue edema, impaired wound healing, bowel anastomotic dehiscence, prolonged postoperative ileus, and pulmonary complications. Conversely, overly restrictive fluid strategies lead to organ hypoperfusion and acute kidney injury. +-------------------------------------------------------------------------+

  • | DYNAMIC VS STATIC VOLUME PARAMETERS |
  • +------------------------------------+------------------------------------+
  • | DYNAMIC PARAMETERS (High Accuracy) | STATIC PARAMETERS (Poor Accuracy) |
  • | - Stroke Volume Variation (SVV) | - Central Venous Pressure (CVP) |
  • | - Pulse Pressure Variation (PPV) | - Mean Arterial Pressure (MAP) |
  • | - Stroke Volume (SV) Response >10% | - Heart Rate (HR) |
  • | - Passive Leg Raise (PLR) | - Hourly Urine Output (UOP) |
  • +------------------------------------+------------------------------------+
  • The Physiology of Dynamic Cardiopulmonary Interactions

During positive-pressure mechanical ventilation, cyclic changes in intrathoracic pressure modulate right and left ventricular loading:

Inspiration (Positive Pressure): Increases intrathoracic pressure → \rightarrow → compresses vena cava and decreases venous return (decreases RV preload) → \rightarrow → temporarily increases LV preload via pulmonary venous squeezing → \rightarrow → peak stroke volume ( S V m a x SV_{max} S V ma x ​ ).

Expiration: Decreased RV stroke volume passes through the pulmonary circulation 2–3 beats later (pulmonary transit time), resulting in minimum LV preload and minimum stroke volume ( S V m i n SV_{min} S V min ​ ).

Dynamic Hemodynamic Indices

Stroke Volume Variation (SVV): Calculated by arterial pulse contour analysis: SVV (%) = S V m a x − S V m i n ( S V m a x + S V m i n ) / 2 × 100 % \text{SVV (\%)} = \frac{SV_{max} - SV_{min}}{(SV_{max} + SV_{min}) / 2} \times 100\% SVV (%) = ( S V ma x ​ + S V min ​ ) /2 S V ma x ​ − S V min ​ ​ × 100%

Normal / Non-responder: SVV < 10 − 12 % \text{SVV} < 10 - 12\% SVV < 10 − 12%

Volume Responder: SVV > 12 − 13 % \text{SVV} > 12 - 13\% SVV > 12 − 13% (indicates patient is operating on the steep ascending limb of the Frank-Starling curve and will increase cardiac output in response to fluid loading).

Pulse Pressure Variation (PPV): Calculated from arterial line waveform systolic-diastolic pressure swings: PPV (%) = P P m a x − P P m i n ( P P m a x + P P m i n ) / 2 × 100 % \text{PPV (\%)} = \frac{PP_{max} - PP_{min}}{(PP_{max} + PP_{min}) / 2} \times 100\% PPV (%) = ( P P ma x ​ + P P min ​ ) /2 P P ma x ​ − P P min ​ ​ × 100%

Volume Responder Threshold: PPV > 12 − 13 % \text{PPV} > 12 - 13\% PPV > 12 − 13%

Fluid Challenge / Stroke Volume Optimization: Administer a defined mini-bolus ( 250 mL 250\text{ mL} 250 mL of balanced crystalloid or colloid over 5–10 minutes) or perform a Passive Leg Raise (PLR) test (autotransfuses ≈ 300 mL \approx 300\text{ mL} ≈ 300 mL of venous blood from lower extremities). A ≥ 10 % \ge 10\% ≥ 10% increase in Stroke Volume (SV) confirms volume responsiveness.

Strict Prerequisites for SVV & PPV Validity

Dynamic parameters are only valid under specific cardiopulmonary conditions:

Controlled Mechanical Ventilation: Mandatory volume-controlled mode with Tidal Volume ≥ 8 mL/kg \ge 8\text{ mL/kg} ≥ 8 mL/kg Predicted Body Weight (PBW) (low tidal volumes < 6 mL/kg <6\text{ mL/kg} < 6 mL/kg generate insufficient intrathoracic pressure swings, causing false-negative SVV).

Absence of Spontaneous Respiratory Efforts: Spontaneous breathing triggers negative intrathoracic pressures, corrupting cyclic waveform variation.

Regular Sinus Rhythm: Cardiac arrhythmias (atrial fibrillation, frequent PVCs) cause beat-to-beat stroke volume variations unrelated to respiration, completely invalidating SVV/PPV.

Closed Thorax: Open thoracotomy eliminates the enclosed intrathoracic pressure chamber.

Normal Intra-Abdominal Pressure: Severe abdominal hypertension (e.g., high-pressure pneumoperitoneum > 15 mmHg >15\text{ mmHg} > 15 mmHg ) artificially elevates SVV.

Loading diagram... Goal-Directed Fluid Therapy & Fluid Responsiveness Algorithm